CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3 + regulatory T cells with respect to lethal prostate cancer
Modern Pathology, ISSN: 0893-3952, Vol: 26, Issue: 3, Page: 448-455
2013
- 85Citations
- 102Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations85
- Citation Indexes85
- 85
- CrossRef57
- Captures102
- Readers102
- 102
Article Description
Prostate cancer represents a major contributor to cancer mortality, but the majority of men with prostate cancer will die of other causes. Thus, a challenge is identifying potentially lethal disease at diagnosis. Conflicting results have been reported when investigating the relationship between infiltration of lymphocytes and survival in prostate cancer. One of the mechanisms suggested is the recruitment of regulatory T cells (T regs ), a subpopulation of T cells that have a role in promoting tumor growth. T regs counteract tumor rejection through suppressive functions on the anti-immune response but their prognostic significance is still unknown. We report here the results of a conducted case–control study nested in a cohort of men treated with transurethral resection of the prostate and diagnosed incidentally with prostate cancer. Cases are men who died of prostate cancer ( n =261) and controls are men who survived >10 years after their diagnosis ( n =474). Infiltration of both T helper and T cytotoxic cells was frequently observed and the majority of the T regs were CD4 +. T helper or T cytotoxic cells were not associated with lethal prostate cancer. However, we found a nearly twofold increased risk of lethal prostate cancer when comparing the highest with the lowest quartile of CD4 + T reg cells (95% confidence interval: 1.3–2.9). Our conclusion is that men with greater numbers of CD4 + T regs in their prostate tumor environment have an increased risk of dying of prostate cancer. Identification of CD4 + T regs in tumor tissue may predict clinically relevant disease at time of diagnosis independently of other clinical factors.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0893395222034457; http://dx.doi.org/10.1038/modpathol.2012.164; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84875209263&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23041830; https://linkinghub.elsevier.com/retrieve/pii/S0893395222034457; https://dx.doi.org/10.1038/modpathol.2012.164
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know